Essa制药 EPIX 深 沪
等待开盘 08-20 09:30:00 美东时间
1.91
0.000
0.00%
华盛通- 最 高1.92
- 今 开1.91
- 成交量 24.21万股
- 最 低 1.91
- 昨 收 1.91
- 总市值 8478.22万
- 52周最高 7.88
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 1.40
- 委 比 90.43%
- 总股本 4438.86万
- 历史最高 245.00
- 量 比 0.58
- 振 幅 0.52%
- 历史最低 1.40
- 每 手 1
- 风险率 1.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ESSA Pharma Q3 EPS $(0.09) Beats $(0.16) Estimate
ESSA Pharma (NASDAQ:EPIX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.16) by 43.75 percent. This is a 43.75 percent increase over losses of $(0.16) per share from the
08-13 21:12
ESSA Pharma To Distribute $80M To Shareholders
SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada, Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, following the Company's receipt of an order from the Supreme
08-07 05:22
ESSA Pharma Announces Tax Implications of Cash Distribution
ESSA Pharma ( ($EPIX) ) has shared an update. On July 31, 2025, ESSA Pharma Inc...
08-01 05:28
ESSA Pharma To Seek Court Approval For Shareholder Payout And Special Meeting Ahead Of Acquisition By XenoTherapeutics
ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit
07-24 04:52
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia Pharmaceuticals Inc. will present at four upcoming investor conferences in August and September 2025 in Boston and New York. The company, utilizing its DiffuSphere™ technology for targeted drug delivery, focuses on addressing unmet medical needs, particularly in pain and inflammatory diseases. Its lead product, EP-104GI, is in Phase 1b/2 trials for EoE, while EP-104IAR recently met key endpoints in a Phase 2b trial for knee osteoarthriti...
07-22 21:17
ESSA Pharma To Be Acquired By XenoTherapeutics; Shareholders Will Receive A Cash Payment Per Common Share That Will Be Determined Based Upon Essa's Cash Balance At Closing After Deducting Certain Transaction Costs, A Reserve For Liabilities And Legal Expenses And A Transaction Fee As Well As Contingent Value Right
Under the terms of the Business Combination Agreement, ESSA shareholders will receive a cash payment per Common Share that will be determined based upon ESSA's cash balance at closing after deducting certain transaction
07-14 20:06
ESSA Pharma Inc. Explores Strategic Alternatives After Clinical Trial Termination
ESSA Pharma Inc. ( ($EPIX) ) has released its Q2 earnings. Here is a breakdown ...
05-10 12:16
ESSA Pharma Q2 EPS $(0.14) Beats $(0.19) Estimate
ESSA Pharma (NASDAQ:EPIX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 30 percent increase over losses of $(0.20) per share from the same
05-08 19:12
Contact The Gross Law Firm by March 25, 2025 Deadline to Join Class Action Against ESSA Pharma Inc.(EPIX)
NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during t...
03-10 17:45
ESSA Pharma Reports Q1 Loss, Explores Strategic Options
ESSA Pharma ( ($EPIX) ) just unveiled an update. ESSA Pharma has reported a net...
02-11 20:50
